End-of-day quote
Other stock markets
|
||
- USD | - |
07-16 | Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly | MT |
07-05 | Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing | MT |
Sales 2024 * | 10.63M 818M | Sales 2025 * | 10.68M 821M | Capitalization | 94.07M 7.23B |
---|---|---|---|---|---|
Net income 2024 * | -53M -4.08B | Net income 2025 * | -49M -3.77B | EV / Sales 2024 * | -0.1 x |
Net cash position 2024 * | 95.15M 7.32B | Net cash position 2025 * | 169M 12.96B | EV / Sales 2025 * | -6.97 x |
P/E ratio 2024 * |
-1.77
x | P/E ratio 2025 * |
-2.01
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.45% |
Latest transcript on ACLS THER
Managers | Title | Age | Since |
---|---|---|---|
Neal Walker
CEO | Chief Executive Officer | 54 | 30/06/12 |
Kevin Balthaser
DFI | Director of Finance/CFO | 37 | 31/12/16 |
Ajay Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Schiff
BRD | Director/Board Member | 58 | 08/08/17 |
Maxine Gowen
BRD | Director/Board Member | 66 | 01/07/19 |
Director/Board Member | 60 | 06/01/20 |
1st Jan change | Capi. | |
---|---|---|
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |